Bristol-Myers Squibb (BMY) Poised for Upside With Registrational Data Ahead

Bristol-Myers Squibb Company (NYSE:BMY) ranks among the stocks with the lowest forward PE ratios. Leerink Partners boosted its price target for Bristol-Myers Squibb Company (NYSE:BMY) to $60 from $54 on January 13, maintaining an Outperform rating on the company’s shares. The firm cited substantial pipeline flexibility in 2026 as the key justification for the higher target.

Leerink decreased its fourth-quarter 2025 earnings per share forecast by 29%, from $1.65 to $1.19, citing expected IPR&D expenses of $1,393 million and licensing income of $222 million.

Moreover, Bristol-Myers Squibb Company (NYSE:BMY) presented a summary of its portfolio readings at a conference on January 12, noting 12 registrational data readings from eight assets expected this year, with the majority representing significant advancement potential. Leerink believes investors are now greatly discounting most pipeline candidates, suggesting huge upside potential if clinical trial findings are favorable.

Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with serious diseases, including cancer, blood disorders, immune conditions, cardiovascular disease, and neurological disorders.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.